Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR

Abstract

Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific secondary somatic mutation, EGFR T790M. Here we describe a family with multiple cases of non-small cell lung cancer associated with germline transmission of this mutation. Four of six tumors analyzed showed a secondary somatic activating EGFR mutation, arising in cis with the germline EGFR mutation T790M. These observations implicate altered EGFR signaling in genetic susceptibility to lung cancer.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Germline EGFR mutation in familial lung cancer.

References

  1. 1

    Kris, M.G. et al. J. Am. Med. Assoc. 290, 2149–2158 (2003).

    CAS  Article  Google Scholar 

  2. 2

    Lynch, T.J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3

    Paez, J.G. et al. Science 304, 1497–1500 (2004).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4

    Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Sordella, R., Bell, D.W., Haber, D.A. & Settleman, J. Science 305, 1163–1167 (2004).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. 6

    Kobayashi, S. et al. N. Engl. J. Med. 352, 786–792 (2005).

    CAS  Article  PubMed  Google Scholar 

  7. 7

    Pao, W. et al. PloS Med. 2, e73 (2005).

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Kwak, E.L. et al. Proc. Natl. Acad. Sci. USA 102, 7665–7670 (2005).

    CAS  Article  PubMed  Google Scholar 

  9. 9

    Daub, H., Specht, K. & Ullrich, A. Nat. Rev. Drug Discov. 3, 1001–1010 (2004).

    CAS  Article  PubMed  Google Scholar 

  10. 10

    Yamamoto, M., Kurosu, T., Kakihana, K., Mizuchi, D. & Miura, O. Biochem. Biophys. Res. Commun. 319, 1272–1275 (2004).

    CAS  Article  PubMed  Google Scholar 

  11. 11

    Blencke, S., Ullrich, A. & Daub, H. J. Biol. Chem. 278, 15435–15440 (2003).

    CAS  Article  PubMed  Google Scholar 

  12. 12

    Blencke, S. et al. Chem. Biol. 11, 691–701 (2004).

    CAS  Article  PubMed  Google Scholar 

  13. 13

    Kosaka, T. et al. Cancer Res. 64, 8919–8923 (2004).

    CAS  Article  PubMed  Google Scholar 

  14. 14

    Han, S.-W. et al. J. Clin. Oncol. 23, 2493–2501 (2005).

    CAS  Article  PubMed  Google Scholar 

  15. 15

    Zhang, C. et al. Nat. Methods 2, 435–441 (2005).

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank K. Shannon and J. Johns for assistance with specimen acquisition. This work was supported in part by the US National Institutes of Health (D.W.B., D.A.H.), the Doris Duke Foundation (D.A.H.), the National Foundation for Cancer Research (D.A.H.) and the V Foundation (J.S.).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Daniel A Haber.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bell, D., Gore, I., Okimoto, R. et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37, 1315–1316 (2005). https://doi.org/10.1038/ng1671

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing